NASDAQ:ABP Abpro Q2 2025 Earnings Report $0.52 0.00 (0.00%) As of 09/23/2026 ProfileEarnings HistoryForecast Abpro EPS ResultsActual EPS-$1.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAbpro Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAbpro Announcement DetailsQuarterQ2 2025Date8/13/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Abpro Earnings HeadlinesAbpro Holdings Faces Nasdaq Delisting, Moves to OTCJune 23, 2026 | theglobeandmail.comAbpro Holdings Directors Resign, Board Seeks ReplacementsJune 22, 2026 | theglobeandmail.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)ABPO Abpro Holdings, Inc.May 6, 2026 | seekingalpha.comAbpro Bio Co. Ltd.April 16, 2026 | barrons.comAbpro Holdings Equity Warrant Exp 12th Nov 2029April 14, 2026 | cnbc.comSee More Abpro Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abpro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abpro and other key companies, straight to your email. Email Address About AbproAbpro (NASDAQ:ABP) is a clinical-stage biotechnology company focused on developing antibody-based therapeutics for cancer and other serious diseases. The company uses its proprietary DiversImmune platform to discover and engineer next-generation antibodies, including bispecific antibodies designed to engage the immune system and target disease-associated proteins. Abpro’s lead product candidate is ABP-100, a bispecific antibody designed to bind HER2 on tumor cells and CD3 on T cells. The company is evaluating ABP-100 as a potential treatment for HER2-expressing cancers. Its broader pipeline includes additional antibody programs at various stages of development. Abpro operates as a biotechnology company serving the global biopharmaceutical market, with research and development activities focused on advancing its proprietary antibody platform and therapeutic candidates. The company is led by co-founder and Chief Executive Officer Ian Chan and became publicly traded on the Nasdaq under the symbol ABP following a business combination in 2024.View Abpro ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
